Nasilin, Abdul Siarip .
HRN: 27-51-22 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/20/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
07/20/2025
07/27/2025
IV
30mg
Q24
PSNB
Waiting Final Action
Indication: ProphylaxisEmpiric Type of Infection: BloodstreamProphylaxis Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes